Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 10, 2024

Nivolumab for Patients With Advanced Renal Cell Carcinoma

ESMO Open

 

Additional Info

ESMO Open
Nivolumab in patients with advanced renal cell carcinoma in France: interim results of the observational, real-world WITNESS study
ESMO Open 2024 Jun 18;9(7)103602, P Barthélémy, L Albigès, B Escudier, B Narciso, P Bigot, M Chehimi, S Emambux, F Calcagno, G Mouillet, JC Eymard, F Schlürmann, S Bailly, D Garbay, JF Berdah, MB Palmaro, MG Goupil, D Spaeth, S Néré, C Quentric, YA Vano, A Thiery-Vuillemin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading